[en] BACKGROUND: Still 30-40% of pediatric acute myeloid leukemia (pedAML) patients relapse. Delineation of the transcriptomic profile of leukemic subpopulations could aid in a better understanding of molecular biology and provide novel biomarkers. METHODS: Using microarray profiling and quantitative PCR validation, transcript expression was measured in leukemic stem cells (LSC, n = 24) and leukemic blasts (L-blast, n = 25) from pedAML patients in comparison to hematopoietic stem cells (HSCs, n = 19) and control myeloblasts (C-blast, n = 20) sorted from healthy subjects. Gene set enrichment analysis was performed to identify relevant gene set enrichment signatures, and functional protein associations were identified by STRING analysis. RESULTS: Highly significantly overexpressed genes in LSC and L-blast were identified with a vast majority not studied in AML. CDKN1A, CFP, and CFD (LSC) and HOMER3, CTSA, and GADD45B (L-blast) represent potentially interesting biomarkers and therapeutic targets. Eleven LSC downregulated targets were identified that potentially qualify as tumor suppressor genes, with MYCT1, PBX1, and PTPRD of highest interest. Inflammatory and immune dysregulation appeared to be perturbed biological networks in LSC, whereas dysregulated metabolic profiles were observed in L-blast. CONCLUSION: Our study illustrates the power of taking into account cell population heterogeneity and reveals novel targets eligible for functional evaluation and therapy in pedAML. IMPACT: Novel transcriptional targets were discovered showing a significant differential expression in LSCs and blasts from pedAML patients compared to their normal counterparts from healthy controls. Deregulated pathways, including immune and metabolic dysregulation, were addressed for the first time in children, offering a deeper understanding of the molecular pathogenesis. These novel targets have the potential of acting as biomarkers for risk stratification, follow-up, and targeted therapy. Multiple LSC-downregulated targets endow tumor suppressor roles in other cancer entities, and further investigation whether hypomethylating therapy could result into LSC eradication in pedAML is warranted.
Disciplines :
Pediatrics Hematology
Author, co-author :
Depreter, Barbara; Ghent University
De Moerloose, Barbara; Ghent University + Cancer Research Institute Ghent
Vandepoele, Karl; Ghent University Hospital + Cancer Research Institute Ghent
Uyttebroeck, Anne; University Hospital Gasthuisberg, Leuven
Van Damme, An; University Hospital Saint-Luc, Brussels
Rasche, M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32, 2167–2177 (2018).
De Moerloose, B. et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: results from protocol DB AML-01. Pediatr. Blood Cancer 66, e27605 (2019).
Abrahamsson, J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J. Clin. Oncol. 29, 310–315 (2011).
De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).
Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738–743 (2004).
Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104–108 (2017).
Hanekamp, D. et al. Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. Br. J. Hematol. 183, 512–516 (2018).
Witte, K. E. et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr. Hematol. Oncol. 28, 91–99 (2011).
Bachas, C. et al. Gene expression profiles associated with pediatric relapsed AML. PLoS ONE 10, e0121730 (2015).
Pigazzi, M. et al. MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia 25, 560–563 (2011).
Jo, A. et al. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia 29, 1076–1083 (2015).
Andersson, A. et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 21, 1198–1203 (2007).
Balgobind, B. V. et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96, 221–230 (2011).
Zangrando, A., Dell’orto, M. C., Te Kronnie, G. & Basso, G. MLL rearrangements in pediatric acute lymphoblastic and myeloblastic leukemias: MLL specific and lineage specific signatures. BMC Med. Genomics 2, 36 (2009).
Ross, M. E. et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104, 3679–3687 (2004).
Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437 (2016).
Majeti, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl Acad. Sci. USA 106, 3396–3401 (2009).
Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17, 1086–1093 (2011).
Forsberg, E. C. et al. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. PLoS ONE 5, e8785 (2010).
Gal, H. et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20, 2147–2154 (2006).
Gentles, A. J., Plevritis, S. K., Majeti, R. & Alizadeh, A. A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304, 2706–2715 (2010).
Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2, 17ra9 (2010).
de Leeuw, D. C. et al. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer Res. 74, 2094–2105 (2014).
Duployez, N., Preudhomme, C. & Cheok, M. A 17-gene-expression profile to improve prognosis prediction in childhood acute myeloid leukemia. Oncotarget 9, 33869–33870 (2018).
Duployez, N. et al. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia. Leukemia 33, 348–357 (2018).
Elsayed, A. H. et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia https://doi.org/10.1038/s41375-019-0604-8 (2019).
Richard-Carpentier, G. & Sauvageau, G. Bringing a leukemic stem cell gene signature into clinics: are we there yet? Cell Stem Cell 20, 300–301 (2017).
Xu, Z. J. et al. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. J. Transl. Med. 17, 102 (2019).
Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, 607–613 (2019).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Reimand, J. et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat. Protoc. 14, 482–517 (2019).
Bolouri, H. et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 24, 103–112 (2018).
Rohrs, S. et al. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol. Cancer 8, 86 (2009).
Landrette, S. F. et al. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11. Blood 105, 2900–2907 (2005).
Fu, S. et al. Overexpression of MYCT1 inhibits proliferation and induces apoptosis in human acute myeloid leukemia HL-60 and KG-1a cells in vitro and in vivo. Front. Pharm. 9, 1045 (2018).
Arora, D. et al. Expression of protein-tyrosine phosphatases in acute myeloid leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. Cell Commun. Signal. 10, 19 (2012).
Peng, L. et al. Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia. Leuk. Lymph. 59, 2423–2430 (2018).
Andries, V. et al. NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest. BMC Cancer 15, 391 (2015).
Korthuis, P. M. et al. CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia. Leukemia 29, 625–635 (2015).
Laverdiere, I. et al. Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. Exp. Hematol. 44, 1039–1043 (2016).
Niu, Y. et al. Distinct prognostic values of Annexin family members expression in acute myeloid leukemia. Clin. Transl. Oncol. 21, 1186–1196 (2019).
Chavez-Gonzalez, A. et al. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Arch. Med. Res. 45, 343–350 (2014).
Darwish, N. H. et al. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget 7, 57811–57820 (2016).
Hanekamp, D., Cloos, J. & Schuurhuis, G. J. Leukemic stem cells: identification and clinical application. Int. J. Hematol. 105, 549–557 (2017).
Dardaei, L., Longobardi, E. & Blasi, F. Prep1 and Meis1 competition for Pbx1 binding regulates protein stability and tumorigenesis. Proc. Natl Acad. Sci. USA 11, 896–905 (2014).
Song, L. et al. Protein tyrosine phosphatases receptor type D is a potential tumour suppressor gene inactivated by deoxyribonucleic acid methylation in paediatric acute myeloid leukaemia. Acta Paediatr. 105, 132–141 (2016).
Jasielec, J., Saloura, V. & Godley, L. A. The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia 28, 1765–1773 (2014).
Yin, X. et al. Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia. Cancer Cell Int. 18, 122 (2018).
Hemmati, S., Haque, T. & Gritsman, K. Inflammatory signaling pathways in preleukemic and leukemic stem cells. Front. Oncol. 7, 265 (2017).
Li, Z. et al. Growth and differentiation effects of Homer3 on a leukemia cell line. Asian Pac. J. Cancer Prev. 14, 2525–2528 (2013).
Stirewalt, D. L. et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47, 8–20 (2008).
Jain, M., Bakhshi, S., Shukla, A. A. & Chauhan, S. S. Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers. Ann. Hematol. 89, 1223–1232 (2010).
Pandey, G., Bakhshi, S., Thakur, B., Jain, P. & Chauhan, S. S. Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia. Leuk. Lymph. 59, 2175–2187 (2018).
Alatrash, G. Targeting cathepsin G in myeloid leukemia. Oncoimmunology 2, e23442 (2013).
Pandey, G. et al. Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia. Am. J. Cancer Res. 9, 2634–2649 (2019).
Liebermann, D. A. & Hoffman, B. Myeloid differentiation (MyD) primary response genes in hematopoiesis. Oncogene 21, 3391–3402 (2002).
Wang, L. et al. Abnormal expression of GADD45B in human colorectal carcinoma. J. Transl. Med. 10, 215 (2012).
Korycka, A., Lech-Maranda, E. & Robak, T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat. Anticancer Drug Discov. 3, 123–136 (2008).
Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591 (2004).
Zi, F. et al. Metformin and cancer: an existing drug for cancer prevention and therapy. Oncol. Lett. 15, 683–690 (2018).
Aries, I. M. et al. EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. Leukemia 28, 1828–1837 (2014).
Zhang, Z. et al. Integrated bioinformatic analysis of microarray data reveals shared gene signature between MDS and AML. Oncol. Lett. 16, 5147–5159 (2018).
Bonardi, F., Fusetti, F., Deelen, P., van Gosliga, D. & Vellenga, E. A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Mol. Cell Proteom. 12, 626–637 (2013).
